查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600716

糖尿病神经病变市场：依治疗类型、疾病类型、通路划分 - 全球预测 2025-2030

Diabetic Neuropathy Market by Treatment Type (Drugs, Physiotherapy), Disorder Type (Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy), Distribution channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年糖尿病神经病变市场估值为35亿美元，预计2024年将达37.2亿美元，复合年增长率为6.37%，预计到2030年将达54亿美元。

糖尿病神经神经病变是糖尿病常见的併发症，伴随长期高血糖引起的神经病变，影响感觉、运动和自主神经系统。糖尿病人口的迅速增加强调了早期诊断和有效管理策略的必要性。糖尿病神经病变治疗的重点是症状管理和减缓疾病进展，并满足医院、专科诊所和居家照护机构患者的需求。该市场的成长得益于糖尿病盛行率的上升、社会意识的提高以及治疗方案的进步，包括Gabapentin和Pregabalin等药物疗法以及物理疗法和新再生疗法等非药物疗法。开发患者友善解决方案的机会比比皆是，包括个人化医疗方法、增强型诊断工具和用于持续监测的可穿戴技术。此外，使用人工智慧来预测疾病的发作和进展有可能彻底改变患者护理。然而，市场拓展面临治疗成本上升、现有产品疗效有限、早期症状不明确而缺乏诊断等挑战。熟练专业人员的短缺进一步使发展中地区的病患管理变得更加复杂。创新者可以透过探索新型止痛药、联合治疗和神经修復技术来克服这些限制。促进生物技术公司和研究机构之间的伙伴关係可以加快开发新药并扩大治疗范围。市场的未来取决于整合医学研究、技术和以患者为中心的护理模式的跨学科创新。实现成长需要对这些快速成长的领域进行投资，并专注于确保创新快速、安全部署的监管途径。透过解决未满足需求管理的技术和方面的问题，公司可以提高其市场地位，并最终改善患者治疗结果和未满足的临床需求。竞争激烈但未来性的市场表明，长期成长有利于采取与不断发展的医疗保健模式一致的整体、综合方法的公司。

主要市场统计
基准年[2023] 35亿美元
预测年份 [2024] 37.2亿美元
预测年份 [2030] 54亿美元
复合年增长率（%） 6.37%

市场动态：快速发展的糖尿病神经病变市场的关键市场洞察

供需的动态交互作用正在改变糖尿病神经病变市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 糖尿病神经病变盛行率上升以及有效治疗方法的需求
    • 提高人们对糖尿病诊断和治疗的认识
    • 政府努力控製糖尿病神经病变
  • 市场限制因素
    • 临床试验失败率高，糖尿病神经病变治疗费用上涨
  • 市场机会
    • 糖尿病神经病变研究领域的拓展
    • 先进药物输送系统的开发
  • 市场挑战
    • 与糖尿病神经病变治疗相关的併发症

波特五力：驾驭糖尿病神经病变市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解糖尿病神经病变市场的外部影响

外部宏观环境因素在塑造糖尿病神经病变市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解糖尿病神经病变市场的竞争格局

糖尿病神经病变市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵糖尿病神经病变市场供应商的绩效评估

FPNV定位矩阵是评估糖尿病神经病变市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 糖尿病神经病变的盛行率和有效治疗方法的需求
      • 提高对糖尿病诊断和治疗的认识
      • 政府管理糖尿病神经病变的倡议
    • 抑制因素
      • 临床试验失败率高，治疗费用高
    • 机会
      • 扩大糖尿病神经病变的研究领域
      • 先进药物输送系统的开发
    • 任务
      • 与糖尿病神经病变治疗相关的併发症
  • 市场区隔分析
    • 治疗类型：药物治疗广泛使用药物来缓解疼痛、稳定神经功能
    • 疾病类型：週边神经病变盛行率增加有利于糖尿病神经病变
    • 通路：网路药局的出现成为便捷的医疗药品通路
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的糖尿病神经病变市场

  • 药物
    • 止痛药
      • 非类固醇消炎剂
      • 阿片类药物
      • 话题
    • 抗惊厥药
      • Gabapentin
      • Pregabalin
      • 托吡酯
    • 抗忧郁症
      • 血清素和正肾上腺素再回收抑制剂
      • SSRI
      • TCA
  • 物理治疗

第七章依疾病类型分類的糖尿病神经病变市场

  • 自主神经病变
  • 局部神经病变
  • 週边神经神经病变
  • 近端神经病变

第八章糖尿病神经病变市场：依通路

  • 诊所
  • 医院
  • 网路药房
  • 零售药房

第九章北美及南美糖尿病神经病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区糖尿病神经病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的糖尿病神经病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Neuralace Medical 完成疼痛性糖尿病神经病变标籤扩展研究 (AT-PDN) 註册，为 FDA 批准突破性非侵入性治疗糖尿病神经病变疼痛铺平道路
    • 拨款 140 万英镑用于开发糖尿病週边神经神经病变的早期检测
    • Horizo​​n Therapeutics核准FDA 批准更新 TEPEZZA (teprotumumab-TRBW) 的适应症语言，以指定在甲状腺眼病 (TED) 患者中的使用，无论疾病活动度或持续时间如何。
    • Praetego 获得美国国家眼科研究所 30 万美元资助，用于开发治疗糖尿病视网膜病变的新型口服药物
    • Abbott、 Medtronic和 Nebro 正在开发 SCS 疗法来治疗週边神经病变。

糖尿病患者 对于糖尿病患者

    • NeuroMetrix 推出週边神经神经病变测试 DPNCheck 2.0
    • Tandem Diavitis Care 完成对胰岛素帮浦製造商 AMF Medical 的收购
    • 宝洁健康 (P&G Health) 与 IDF 合作解决糖尿病患者的周边神经病变
    • Glenmark Pharma 推出治疗糖尿病併发症的药物
    • Regency Pharmaceuticals 宣布完成糖尿病週边神经神经病变2 期试验的入组工作，并获得 930 万美元的 B 轮资金筹措。
    • 医疗科技Start-UpsYostra Labs 已筹集 40 亿卢比种子轮资金，用于帮助患有慢性病的患者。
    • FDA核准PENS 装置治疗糖尿病週边神经神经病变相关疼痛
    • FDA核准Medtronic神经刺激设备治疗糖尿病週边神经病变疼痛
    • RMH 与澳洲糖尿病创新加速器中心合作
    • Withings 收购医疗设备製造商 Impet Medical

公司名单

  • Stem Cell Care India
  • NeuroMetrix, Inc.
  • Astellas Pharma Inc.
  • Abbott Laboratories
  • Novartis AG
  • AdventHealth
  • AstraZeneca PLC
  • Eli Lilly and Company
  • The Procter & Gamble Company
  • Sanofi SA
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Harmonium Pharma srl
  • Boston Scientific Corporation
  • Vertex Pharmaceuticals Incorporated
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Bauerfeind AG
  • Medtronic PLC
  • Bayer AG
  • Regenacy Pharmaceuticals, Inc.
  • Viatris Inc.
  • Alkem Labs
  • Trevena, Inc.
  • Collegium Pharmaceutical, Inc.
  • Glenmark Pharmaceuticals Limited
  • Praetego, LLC
  • Nevro Corp.
  • Boehringer Ingelheim International GmbH
  • Winsantor, Inc.
  • Daiichi Sankyo Company, Limited
  • Grunenthal GmbH
Product Code: MRR-4348D129FA14

The Diabetic Neuropathy Market was valued at USD 3.50 billion in 2023, expected to reach USD 3.72 billion in 2024, and is projected to grow at a CAGR of 6.37%, to USD 5.40 billion by 2030.

Diabetic neuropathy, a frequent complication of diabetes, involves nerve damage due to prolonged high blood glucose levels, affecting sensory, motor, and autonomic nervous systems. The burgeoning diabetic population underscores the critical need for early diagnosis and effective management strategies. Diabetic neuropathy treatments hinge on symptom management and slowing disease progression, serving patient needs across hospitals, specialty clinics, and home care settings. This market's growth is fueled by rising diabetes prevalence, heightened public awareness, and advancements in therapeutic options, including medications like gabapentin and pregabalin, and non-pharmacological treatments such as physiotherapy and emerging regenerative therapies. Opportunities abound in developing personalized medicine approaches, enhanced diagnostic tools, and patient-friendly solutions such as wearable technology for continuous monitoring. Moreover, leveraging artificial intelligence to predict disease onset and progression could revolutionize patient care. However, market expansion faces challenges, including the high cost of treatments, limited efficacy of current offerings, and under-diagnosis due to vague symptomatology at early stages. A lack of skilled professionals further complicates patient management in developing regions. Innovators can target these limitations by exploring novel analgesics, combination therapies, and neural repair techniques. Fostering partnerships between biotech firms and research institutions could expedite new drug development and expand treatment accessibility. The market's future hinges on interdisciplinary innovations that integrate medical research, technology, and patient-centered care models. Capturing growth demands investment in these burgeoning areas, with attention to regulatory pathways that ensure quick yet safe deployment of innovations. By addressing both technological and educational facets of diabetic neuropathy management, firms can enhance their market position, ultimately leading to improved patient outcomes and unmet clinical needs. The market's nature as highly competitive yet promising suggests long-term growth will favor those adopting a holistic, integrated approach in line with evolving healthcare paradigms.

KEY MARKET STATISTICS
Base Year [2023] USD 3.50 billion
Estimated Year [2024] USD 3.72 billion
Forecast Year [2030] USD 5.40 billion
CAGR (%) 6.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Neuropathy Market

The Diabetic Neuropathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diabetic neuropathy and the need for effective treatment methods
    • Increasing awareness pertaining to diagnosis & treatment of diabetes
    • Government initiatives for the management of diabetic neuropathy
  • Market Restraints
    • High failure rate in clinical trials and high cost of diabetic neuropathy treatment
  • Market Opportunities
    • Widening diabetic neuropathy research areas
    • Development of advanced drug delivery systems
  • Market Challenges
    • Complications associated with diabetic neuropathy treatment

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Neuropathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Neuropathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Neuropathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Neuropathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Neuropathy Market

A detailed market share analysis in the Diabetic Neuropathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Neuropathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Neuropathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Stem Cell Care India, NeuroMetrix, Inc., Astellas Pharma Inc., Abbott Laboratories, Novartis AG, AdventHealth, AstraZeneca PLC, Eli Lilly and Company, The Procter & Gamble Company, Sanofi S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Pfizer Inc., Harmonium Pharma s.r.l., Boston Scientific Corporation, Vertex Pharmaceuticals Incorporated, Dr. Reddy's Laboratories Ltd., Lupin Limited, Bauerfeind AG, Medtronic PLC, Bayer AG, Regenacy Pharmaceuticals, Inc., Viatris Inc., Alkem Labs, Trevena, Inc., Collegium Pharmaceutical, Inc., Glenmark Pharmaceuticals Limited, Praetego, LLC, Nevro Corp., Boehringer Ingelheim International GmbH, Winsantor, Inc., Daiichi Sankyo Company, Limited, and Grunenthal GmbH.

Market Segmentation & Coverage

This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Drugs and Physiotherapy. The Drugs is further studied across Analgesics, Anticonvulsants, and Antidepressant. The Analgesics is further studied across Non-Steroidal Anti-Inflammatory Drugs, Opioids, and Topical. The Anticonvulsants is further studied across Gabapentin, Pregabalin, and Topiramate. The Antidepressant is further studied across Serotonin & Norepinephrine Reuptake Inhibitors, SSRIs, and TCAs.
  • Based on Disorder Type, market is studied across Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy, and Proximal Neuropathy.
  • Based on Distribution channel, market is studied across Clinics, Hospitals, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
      • 5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
      • 5.1.1.3. Government initiatives for the management of diabetic neuropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Widening diabetic neuropathy research areas
      • 5.1.3.2. Development of advanced drug delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Complications associated with diabetic neuropathy treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
    • 5.2.2. Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
    • 5.2.3. Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Neuropathy Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Drugs
    • 6.2.1. Analgesics
      • 6.2.1.1. Non-Steroidal Anti-Inflammatory Drugs
      • 6.2.1.2. Opioids
      • 6.2.1.3. Topical
    • 6.2.2. Anticonvulsants
      • 6.2.2.1. Gabapentin
      • 6.2.2.2. Pregabalin
      • 6.2.2.3. Topiramate
    • 6.2.3. Antidepressant
      • 6.2.3.1. Serotonin & Norepinephrine Reuptake Inhibitors
      • 6.2.3.2. SSRIs
      • 6.2.3.3. TCAs
  • 6.3. Physiotherapy

7. Diabetic Neuropathy Market, by Disorder Type

  • 7.1. Introduction
  • 7.2. Autonomic Neuropathy
  • 7.3. Focal Neuropathy
  • 7.4. Peripheral Neuropathy
  • 7.5. Proximal Neuropathy

8. Diabetic Neuropathy Market, by Distribution channel

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals
  • 8.4. Online Pharmacy
  • 8.5. Retail Pharmacy

9. Americas Diabetic Neuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetic Neuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetic Neuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
    • 12.3.2. GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
    • 12.3.3. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
    • 12.3.4. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
    • 12.3.5. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment

a diabetic for diabetic

    • 12.3.6. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
    • 12.3.7. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
    • 12.3.8. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
    • 12.3.9. Glenmark Pharma launched drug for diabetic patients with comorbidities
    • 12.3.10. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
    • 12.3.11. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
    • 12.3.12. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy
    • 12.3.13. FDA cleared Medtronic's neurostimulator for diabetic peripheral neuropathy pain
    • 12.3.14. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
    • 12.3.15. Withings acquired Devicemaker Impeto Medical

Companies Mentioned

  • 1. Stem Cell Care India
  • 2. NeuroMetrix, Inc.
  • 3. Astellas Pharma Inc.
  • 4. Abbott Laboratories
  • 5. Novartis AG
  • 6. AdventHealth
  • 7. AstraZeneca PLC
  • 8. Eli Lilly and Company
  • 9. The Procter & Gamble Company
  • 10. Sanofi S.A.
  • 11. Merck KGaA
  • 12. Teva Pharmaceutical Industries Ltd.
  • 13. Novo Nordisk A/S
  • 14. Pfizer Inc.
  • 15. Harmonium Pharma s.r.l.
  • 16. Boston Scientific Corporation
  • 17. Vertex Pharmaceuticals Incorporated
  • 18. Dr. Reddy's Laboratories Ltd.
  • 19. Lupin Limited
  • 20. Bauerfeind AG
  • 21. Medtronic PLC
  • 22. Bayer AG
  • 23. Regenacy Pharmaceuticals, Inc.
  • 24. Viatris Inc.
  • 25. Alkem Labs
  • 26. Trevena, Inc.
  • 27. Collegium Pharmaceutical, Inc.
  • 28. Glenmark Pharmaceuticals Limited
  • 29. Praetego, LLC
  • 30. Nevro Corp.
  • 31. Boehringer Ingelheim International GmbH
  • 32. Winsantor, Inc.
  • 33. Daiichi Sankyo Company, Limited
  • 34. Grunenthal GmbH

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIABETIC NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIABETIC NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEUROPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 327. DIABETIC NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 328. DIABETIC NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023